Dr. Reddy's Laboratories Ltd. Sponsored ADR Stock

$14.51

0.62% today

NYSE, Aug 22, 10:00 pm CET

ISIN

US2561352038

Symbol

RDY

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Dr. Reddy's Laboratories Ltd. Sponsored ADR Stock price

$14.51

+2.49 20.72% 5Y

NYSE, Closing price Fri, Aug 22 2025

+0.09 0.62%

ISIN

US2561352038

Symbol

RDY

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$11.9b

Enterprise Value

Net debt

Cash

Shares outstanding

Valuation (TTM | estimate)

P/E

18.5 | 17.3

P/S

3.1 | 3.0

EV/Sales

- | -

EV/FCF

P/B

Dividends

DPS

$0.09

Yield 1Y | 5Y

0.6% | 0.6%

Growth 1Y | 5Y

-3.9% | 6.5%

Payout 1Y | 3Y

12.2% | 12.3%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$3.8b | $4.0b

EBITDA

$1.0b | $1.1b

EBIT

$794.0m | $850.8m

Net Income

$650.8m | -

Free Cash Flow

Growth (TTM | estimate)

Revenue

15.8% | 7.3%

EBITDA

9.2% | 7.1%

EBIT

6.7% | 5.9%

Net Income

2.1% | -

Free Cash Flow

Financial Health

Equity Ratio

67.9%

Return on Equity

16.9%

ROCE

ROIC

Debt/Equity

EPS

$0.8

FCF per Share

Short interest

2.3%

Employees

27k

Rev per Employee

$140.0k

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Get Started for Free Today

Dr. Reddy's Laboratories Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

44 Analysts have issued a Dr. Reddy's Laboratories Ltd. Sponsored ADR forecast:

20x Buy

45%

11x Hold

25%

13x Sell

30%

More details on Analyst Estimates Including Price Targets

44 Analysts have issued a Dr. Reddy's Laboratories Ltd. Sponsored ADR forecast:

Buy

45%

Hold

25%

Sell

30%

Analyst Estimates with Stock Price Targets

Financial data from Dr. Reddy's Laboratories Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	3,840 3,840	16% 16% 100%
- Direct Costs	1,215 1,215	25% 25% 32%
Gross Profit	2,625 2,625	12% 12% 68%
- Selling and Administrative Expenses	1,138 1,138	21% 21% 30%
- Research and Development Expense	- -	- -
EBITDA	1,000 1,000	9% 9% 26%
- Depreciation and Amortization	206 206	20% 20% 5%
EBIT (Operating Income) EBIT	794 794	7% 7% 21%
Net Profit	651 651	2% 2% 17%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Dr. Reddy's Laboratories Ltd. Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

4 days ago

Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.

Extrovis AG Bahnhof Park 46340, Baar, Switzerland Media Relations Contact Madhu Marur madhu.marur@extrovis.com Press Release Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. Baar, Switzerland; August 14, 2025 Extrovis AG, a global pharmaceutical company focused on research-driven in...

Neutral

Seeking Alpha

●

30 days ago

Dr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call Transcript

Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q1 2026 Earnings Conference Call July 23, 2025 10:00 AM ET Company Participants Erez Israeli - CEO & Member of the Management Council Mannam Venkatanarasimham - CFO & Member of the Management Council Richa Periwal - Head of Investor Relations and Analytics Conference Call Participants Abdulkader Puranwala - ICICI Securities Limited, Research Division...

Neutral

Business Wire

●

about one month ago

Dr. Reddy's Q1FY26 Financial Results

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #ConsolidatedFinancialResults--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2025.

More Dr. Reddy's Laboratories Ltd. Sponsored ADR News

Company Profile

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Head office	India
CEO	Mr. Israeli
Employees	27,048
Founded	1984
Website	www.drreddys.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now